NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis → HUGE BUY ALERT: Move Fast, Musk... (From Stansberry Research) (Ad) Free SAVA Stock Alerts $23.33 +2.71 (+13.14%) (As of 05:27 PM ET) Add Compare Share Share Today's Range$21.48▼$23.4650-Day Range$18.44▼$26.1152-Week Range$12.32▼$32.10Volume1.79 million shsAverage Volume795,404 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$124.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside431.5% Upside$124.00 Price TargetShort InterestBearish32.07% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.17Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.01) to $1.67 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector942nd out of 2,771 stocksPharmaceutical Preparations Industry416th out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted32.07% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently increased by 8.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 1.8 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Cassava Sciences this week, compared to 5 articles on an average week.Search InterestOnly 32 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($2.01) to $1.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -10.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -10.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesMay 10, 2024 | markets.businessinsider.comSAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024May 10, 2024 | msn.comCassava swings to Q1 profit as more patients finish simufilam phase 3 trialsMay 10, 2024 | msn.comCassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?May 10, 2024 | globenewswire.comCassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamMay 10, 2024 | seekingalpha.comAnnovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's BoxMay 8, 2024 | msn.comCassava Sciences raises over $125M from warrant distributionMay 8, 2024 | globenewswire.comCassava Sciences Announces Over $125 Million Raised from Warrant DistributionMay 1, 2024 | msn.comCassava Sciences files for mixed shelf offeringMay 1, 2024 | msn.com27 Best Things to Do in San Francisco, CaliforniaMay 1, 2024 | msn.comCassava: The perilous past and promising future of a toxic but nourishing cropMay 1, 2024 | globenewswire.comTomorrow is Last Day to Trade SAVAW Warrants on NASDAQApril 30, 2024 | msn.comAATF launches mechanised cassava processing plant in OyoApril 30, 2024 | investorplace.comStock Market Crash Warning: Don't Get Caught Holding These 3 Biotech StocksApril 28, 2024 | msn.comExpensive sanitary pads: Agony of girls using clothes for menstruationApril 27, 2024 | msn.comCenterpiece program has crashed and burnedApril 27, 2024 | msn.comHow to grow cocoyamsApril 26, 2024 | msn.comExamining the impact of gene-based breeding on agriculture and medicineApril 26, 2024 | msn.comAdvancing cassava brown streak disease resistanceApril 20, 2024 | msn.comHow Western food imports are fuelling obesity in Pacific nationsApril 19, 2024 | finance.yahoo.comCassava Sciences, Inc. (SAVA)April 15, 2024 | globenewswire.comRedemption Date Announced for WarrantsApril 5, 2024 | bizjournals.comAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesApril 4, 2024 | msn.comStrong quake rocks Taiwan, tsunami warnings issuedApril 3, 2024 | ft.comCan Africa one day help feed the world’s growing population?April 2, 2024 | stockhouse.com24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaSee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$124.00 High Stock Price Target$124.00 Low Stock Price Target$124.00 Potential Upside/Downside+445.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.81% Return on Assets-52.32% Debt Debt-to-Equity RatioN/A Current Ratio9.13 Quick Ratio9.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book6.98Miscellaneous Outstanding Shares43,250,000Free Float37,970,000Market Cap$983.51 million OptionableOptionable Beta-0.38 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.2MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $460kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $425kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $435kDr. George Thornton Ph.D.Senior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsTyra BiosciencesNASDAQ:TYRAImmunomeNASDAQ:IMNMOcular TherapeutixNASDAQ:OCULABIVAX Société AnonymeNASDAQ:ABVXARS PharmaceuticalsNASDAQ:SPRYView All CompetitorsInsiders & InstitutionsCANADA LIFE ASSURANCE CoBought 5,594 shares on 5/14/2024Ownership: 0.022%EntryPoint Capital LLCBought 2,127 shares on 5/14/2024Ownership: 0.005%Vanguard Group Inc.Bought 31,854 shares on 5/10/2024Ownership: 5.449%State Board of Administration of Florida Retirement SystemBought 650 shares on 5/9/2024Ownership: 0.028%Susquehanna Portfolio Strategies LLCSold 4,986 shares on 5/7/2024Ownership: 0.244%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price target for 2024? 1 Wall Street research analysts have issued 12 month price targets for Cassava Sciences' shares. Their SAVA share price targets range from $124.00 to $124.00. On average, they predict the company's share price to reach $124.00 in the next year. This suggests a possible upside of 431.5% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2024? Cassava Sciences' stock was trading at $22.51 at the beginning of the year. Since then, SAVA stock has increased by 3.6% and is now trading at $23.33. View the best growth stocks for 2024 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares Neuroscience and Healthcare ETF (IBRN).iShares U.S. Pharmaceuticals ETF (IHE). When did Cassava Sciences' stock split? Cassava Sciences shares split before market open on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were issued to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.45%), Gallacher Capital Management LLC (1.35%), Clear Creek Financial Management LLC (0.32%), Susquehanna Portfolio Strategies LLC (0.24%), Simplex Trading LLC (0.00%) and Essex LLC (0.12%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAVA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
